About Us - Avicanna

About Avicanna

About

Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments

Founded in 2016 in Toronto, Canada. Avicanna has strictly focused on the medical applications and potential of cannabinoids and has dedicated 9+ years to R&D and clinical development of its proprietary products. Supported by its Canadian scientific platform, Avicanna has successfully commercialized its proprietary products into 23 international markets. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

Market Segments

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products

Four Commercial Stage Business Pillars

Avicanna’s Scientific Platform Has Resulted In 30+ Commercial and Proprietary Formulations and Products

Including medical cannabis, medical cannabis care, Pharmaceutical pipeline and active pharmaceutical ingredients

Medical Cannabis Products

Medical Cannabis Care Platform

Pharmaceutical Pipeline

Active Pharmaceutical Ingredients

Medical Cannabis Formulary (RHO Phyto™)

Medical Cannabis Products and RHO Phyto

The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.

Pharmaceutical Pipeline

Pharmaceutical Candidates Designed to Address 5 Major Clinical Indications

Leveraging the Company’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific candidates that are in various stages of clinical development. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.

Medical Cannabis Care Platform (MyMedi.ca)

MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.

Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Active pharmaceutical ingredients (“API”) supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms high-quality CBD, THC and CBG flower and API to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.